Citadel Advisors
CNTA

Citadel Advisors’s Centessa Pharmaceuticals CNTA Stock Holding History

Citadel Advisors’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.91M Buy
48,200
+10,800
+29% +$276K ﹤0.01% 6145
2025
Q4 		$935K Sell
37,400
-57,600
-61% -$1.46M ﹤0.01% 7546
2025
Q3 		$2.3M Buy
95,000
+55,000
+138% +$978K ﹤0.01% 5784
2025
Q2 		$526K Buy
40,000
+22,800
+133% +$289K ﹤0.01% 8513
2025
Q1 		$247K Buy
17,200
+16,800
+4,200% +$275K ﹤0.01% 10013
2024
Q4 		$6.7K Sell
400
-29,100
-99% -$482K ﹤0.01% 13780
2024
Q3 		$472K Buy
29,500
+26,500
+883% +$325K ﹤0.01% 8387
2024
Q2 		$27.1K Sell
3,000
-2,000
-40% -$19K ﹤0.01% 12365
2024
Q1 		$56.5K Buy
5,000
+1,000
+25% +$9.47K ﹤0.01% 12056
2023
Q4 		$31.8K Buy
4,000
+1,900
+90% +$12.7K ﹤0.01% 12218
2023
Q3 		$13.6K Sell
2,100
-3,200
-60% -$21.9K ﹤0.01% 12914
2023
Q2 		$32.8K Buy
+5,300
New +$25.1K ﹤0.01% 12266
2023
Q1 		– Sell
-1,000
Closed -$3.1K – 14807
2022
Q4 		$3.1K Buy
+1,000
New +$3.71K ﹤0.01% 14250

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Citadel Advisors's CNTA Position: Q1 2026 in Review

Citadel Advisors increased its Centessa Pharmaceuticals (CNTA) stake by 15% in Q1 2026, buying an estimated $2M and bringing the position to 598,197 shares worth $23.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2123.

Citadel Advisors first reported a position in CNTA in Q2 2021 and has held it in 18 quarters since. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Citadel Advisors held 598,197 shares of Centessa Pharmaceuticals worth $23.8M as of Q1 2026.
  • Citadel Advisors bought 78,235 Centessa Pharmaceuticals shares in Q1 2026, an estimated $2M.
  • Centessa Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2123 holding.
  • Citadel Advisors first reported a position in Centessa Pharmaceuticals in Q2 2021 and has held it in 18 quarters since.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.